Skip to main content

Table 1 Patient and tumor characteristics in all patients

From: Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

Characteristic SHERBOC no(n = 525) SHERBOC yes(n = 125)
Age at study entry (years) 60.9 (13.1) 61.1 (11.9)
BMI (kg/m2) 26.6 (5.9) 26.0 (5.6)
Time from diagnosis to metastasis (years) 6.0 (6.5) 6.9 (7.5)
Tumor grade
 1 38 (7.8) 13 (12.5)
 2 333 (68.4) 75 (72.1)
 3 116 (23.8) 16 (15.4)
ECOG score
 0 251 (50.3) 82 (67.8)
 1 192 (38.5) 33 (27.3)
  ≥ 2 56 (11.2) 6 (5.0)
Concomitant diseases
 0 or 1 242 (46.4) 62 (50.4)
 2 to 4 192 (36.8) 46 (37.4)
  ≥ 5 88 (16.9) 15 (12.2)
Metastasis pattern
 Brain 48 (9.2) 4 (3.3)
 Visceral 237 (45.3) 42 (34.1)
 Bone 88 (16.8) 29 (23.6)
 Other 150 (28.7) 48 (39.0)
HRG test
 Negative 18 (47.4)a
 Positive 14 (36.8)a
 Not evaluable 6 (15.8)a
Ever received chemotherapy
 No 279 (53.1) 125 (100.0)
 Yes 246 (46.9) 0 (0.0)
Ever received endocrine therapy
 No 109 (20.8) 12 (9.6)
 Yes 416 (79.2) 113 (90.4)
Ever received fulvestrant
 No 356 (67.8) 125 (100.0)
 Yes 169 (32.2) 0 (0.0)
Previous CDK4/6i documented
 No 405 (77.1) 4 (3.2)b
 Yes 120 (22.9) 121 (96.8)
SHERBOC line
 1 290 (55.2) 117 (93.6)
 2 235 (44.8) 8 (6.4)
  1. BMI Body mass index; ECOG Eastern Cooperative Oncology Group; HRG Heregulin. CDK4/6i CDK4/6 inhibitor
  2. Means and standard deviation (SD) are shown for continuous characteristics, and frequency and percentage for categorical characteristics
  3. a Percentages refer only to the 38 patients for whom a testing was done. For the rest of the population no test results are available due to the early termination of the trial
  4. bThese patients were confirmed to be clinically eligible for SHERBOC despite CDK4/6i was not documented yet at time of database closure
\